Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2020—Myriad Genetics announced that the FDA has approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor olaparib (Lynparza, AstraZeneca). BRACAnalysis CDx is the first FDA-approved genetic test for this indication, the company reports. Myriad Genetics, 801-584-3600
February 2020—The FDA authorized marketing of the Cobas VivoDx MRSA (Roche Molecular Systems) diagnostic test based on bacterial viability and novel technology to detect methicillin-resistant Staphylococcus aureus bacterial colonization. The Cobas VivoDx MRSA test uses a new bacteriophage technology based on bioluminescence to detect MRSA from nasal swab samples in as few as five hours compared with 24 to 48 hours for conventional culture. The FDA reviewed data from performance studies in which the Cobas VivoDx MRSA test correctly identified
February 2020—Karius announced that JAMA Oncology published a clinical study showing that the Karius test detected bloodstream infections before the onset of clinical symptoms in high-risk pediatric patients with relapsed or refractory leukemia (Goggin KP, et al. Epub ahead of print Dec. 19, 2019. doi:10.1001/jamaoncol.2019.4120). The study was performed by researchers at St. Jude Children’s Research Hospital.
February 2020—Verichem Laboratories announced the availability of its HDL Cholesterol Verifier kit intended for the calibration verification of HDL and LDL cholesterol assays. The kit contains high-density and low-density lipoprotein cholesterol from human serum in a ready-to-use, liquid stable format that is free of surfactants, glycols, and azide.
February 2020—The FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting. Enhertu is a human epidermal growth factor receptor 2–directed antibody and topoisomerase inhibitor conjugate.
February 2020—Siemens Healthineers announced the availability of its Enhanced Liver Fibrosis testing service in the United States, excluding New York State, and Puerto Rico. The testing service is provided by the Siemens Healthcare Laboratory.
January 2020—Olympus introduced its Slideview VS200 slide scanner, designed to capture high-resolution images for quantitative analysis for brain, cancer, and stem cell research, as well as drug discovery. The scanner uses Olympus X Line objectives, which are designed to deliver flatter images with a wide field of view and no intensity fall off at the periphery, improve numerical aperture, and offer a wider range of chromatic correction.
January 2020—ALPCO announced that the FDA granted its Calprotectin Chemiluminescence ELISA 510(k) clearance. It is intended for in vitro diagnostic use as an aid in the diagnosis of inflammatory bowel disease, specifically Crohn’s disease and ulcerative colitis, and as an aid in the differentiation of IBD from irritable bowel syndrome, in conjunction with other clinical and laboratory findings.
January 2020—Personal Genome Diagnostics received the CE mark for the PGDx Elio Tissue Complete assay. The panel is a 507-gene test for somatic alterations that detects single nucleotide variants, small indels, amplifications, rearrangements, microsatellite instability, and tumor mutation burden.
January 2020—Genentech announced positive data from the phase three IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced nonsquamous and squamous non-small cell lung cancer without ALK or EGFR mutations.
